• Latest
    • Big pharma
    • Biotechnology
    • CRISPR
    • Generics
    • Unified Patent Court
  • Regions
    • Americas
    • Europe
    • Asia
    • Asia-Pacific
  • Careers
  • Events
    • Conferences
    • Conference Videos
    • Webinars
  • Directory
  • Magazines
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Subscribe
  • Home
  • Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate
18 March 2021

Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate

The Patent Trial and Appeal Board is an important forum for determining a US patent’s validity. Since 2012, when inter partes review of US patents began, the PTAB’s cancellation rate for challenged patents has varied dramatically.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025

Editor's picks

Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Killing the golden goose of US drug innovation (Part I): Follow the money
10 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025

More features

Latham scoops Simmons partner for its London office
Protect early, partner wisely: In-house tips for medtech startups
Data in the age of AI and why its value lies in quality, not quantity
Simmons loses another senior with litigator’s German move
Morgan Lewis adds regulatory partner to London office
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
Stress, anxiety, burnout: ‘Real change needed’ in law
Gilead blocks HIV drug generics for more than 10 years

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin